Author:
de Kruijf Petra,Lim Herman D.,Overbeek Saskia A.,Zaman Guido J.R.,Kraneveld Aletta D.,Folkerts Gert,Leurs Rob,Smit Martine J.
Reference22 articles.
1. The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor;Ahuja;J. Biol. Chem.,1996
2. Contrasting roles for CXCR2 during experimental colitis;Ajuebor;Exp. Mol. Pathol.,2004
3. New molecular targets for the treatment of neutrophilic diseases;Barnes;J. Allergy Clin. Immunol.,2007
4. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury;Bertini;Proc. Natl Acad. Sci. USA,2004
5. SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor;Bradley;Br. J. Pharmacol.,2009
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献